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A B S T R A C T   
The main antiviral drug-cyclodextrin interactions, changes in physicochemical and physiological properties of 
the most commonly used virucides are summarized. The potential complexation of antiviral molecules against 
the SARS-Cov2 also pointed out the lack of detailed information in designing effective and general medicines 
against viral infections. The principal problem of the current molecules is the 3D structures of the currently 
active compounds. Improving the solubility or bioavailability of antiviral molecules is possible, however, there is 
no universal solution, and the complexation experiments dominantly use the already approved cyclodextrin 
derivatives. This review discusses the basic properties of the different cyclodextrin derivatives, their potential in 
antiviral formulations, and the prevention and treatment of viral infections. The biologically active new cyclo-
dextrin derivatives are also discussed.   
1. Introduction 
Cyclodextrins (CDs) are natural oligosaccharides of cyclic structures, 
in which the glucopyranoside (Glcp) units are connected with α(1 → 4) 
glycosidic bond. The 5–9 membered natural CDs have more or less 
symmetric cavities. In the <5 membered CDs no real holes, while in the 
>9 membered macrocycles more distorted, many times more cavities 
exist. The most common CDs have a unique structure where the sec-
ondary hydroxyl region of the Glcp units forms a very strong, and the 
more flexible primary hydroxyls form a slightly less hydrophilic barrier 
for the significantly less hydrophilic cavity as shown in Figs. 1 and 2. 
Although the cavity is only less hydrophilic and less polar than hy-
droxyl rims, it can form complexes with geometrically suitable very 
hydrophilic or polar groups, too. CDs can capture neutral molecules, 
various inorganic and organic salts, acids, or bases by a full or partial 
inclusion through coordination with CD hydroxyls. Strong bases can 
form salts with CD hydroxyls. The hollow structure of CDs allows the 
formation of inclusion complexes, but a real inclusion can frequently 
exist in crystalline structures only. In solutions, usually, the guest 
molecule freely moves in- and outward the cavity since the complexa-
tion process is a dynamic equilibrium. The composition and (apparent) 
complex stability constants - derived from the complex equilibrium 
equation (Eq. (1)) - characterize the inclusion complexes. Due to 
mathematical limitations, the calculated complex stability constant is 
always apparent because the calculations neglect the less abundant 
other complex compositions. 
x CD+ y Guest⇄CDx Guesty⇒Kxy =
[
CDx Guesty




Eq. 1  
where x and y refer to the stoichiometry and [CDx Guesty], [CDfree], 
[Guestfree] are the concentrations of the species in mol/L (M) unit. 
Although the GRAS list [1] of food additives contains numerous CDs, 
only a few are accepted for pharmaceutical uses, particularly in the 
parenteral drug compositions. 
The apparent complex stability constants of the most common, 1:1 
complexes are in the range of 300–800 M− 1 [2]. It means, to put it 
simply, that a ’complexed’ guest molecule stays for an average of 
300–600 times longer close to the CD cavity than when solvated freely in 
the solvent. Various tricks can shift this dynamic equilibrium to get the 
drug molecules more complexed than free. 
Natural CDs form numerous crystalline complexes with various 
blood components [252], making them more suitable for topical or oral 
administration than for parenteral administration. Currently, among the 
derivatized CDs, (2-hydroxy)propylated βCD (HPβCD) and 4-sulfobuty-
lated (SBβCD or SBECD) are permitted for parenteral drug carriers 
only. For topical administration, the European Medical Agency (EMA) 
approved the randomly methylated βCD (RAMEB), too [3]. 
The number of antiviral drugs is more limited than the antibiotics 
and is actually just over 100. Most antiviral medicines are administered 
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in topical or parenteral formulations. A common problem with these 
compounds is that they are poorly soluble in water or physiologically 
buffered saline (PBS) and usually have poor gastrointestinal absorption. 
The low water solubility is usually associated with moderate to high 
logP values (logarithm of 10 of octanol-water concentration distribution 
ratio, which characterizes the molecular lipophilicity). The logP values 
can be calculated in computers, and the fit of the whole or partially (in 
the case of large molecules) into the cavity needs geometrical consid-
erations. Although in silico calculations can help the scientist in the a 
priori selection of an appropriate guest for complexation, the best 
complexing CD derivatives are the statistically derivatized CDs, which 
are poorly suitable for computer simulations. 
In general, the comparison of various publications (articles, pro-
ceedings papers, or patents) is complicated, and many times difficult to 
figure out the depth of the mentions upon the first look at the publica-
tion. It is particularly true for the filed patents in which practically all 
new potential drug formulations mention CDs, blocking their future use, 
independently from the usefulness. In the literature analysis, to reduce 
crowdedness in Figs. 1–4, patents have been removed, and the graphs 
show only relative numbers due to the many overlaps. The absolute 
numbers have few meanings in comparison. Our literature survey used 
the major internet databases, namely ScienceDirect®, SciFinder®, and 
Web of Science®. 
The CDs can serve.  
a) as additives, either as solubility and bioavailability enhancers or 
drug stabilizers [4].  
b) as analytical aid in drug analysis [5].  
c) as a virucidal agent [6–9].  
d) destruction material for virus protein/lipid shell [10–13].  
e) as multivalent antigen vector [14–16].  
f) vaccine adjuvant [17–22].  
g) antibody stabilization [22]. 
The line between categories is not sharp, and many authors often set 
up similar groups or possibly create other subcategories in technical 
papers. Although both CD and viral literature are enormous, their 
intersection is minimal. The dominant part of articles and patents deals 
with the antiviral drug/CD complexes, and to a somehow less extent, 
antiviral drug analysis. The last four categories together, which show the 
direct effect of CDs in antiviral therapy, account for less than 3% of all 
CD publications. Fig. 3a shows the literature distribution of CD publi-
cations within the direct antiviral use of CDs (patents not included). If 
we dig a little deeper and remove the reports on the analytical appli-
cations, the picture is even worse, not only for the whole CD literature 
but also within these subgroups, as shown in Fig. 3b. Although some CD- 
lipid/membrane interaction has been known for a long time, the most 
known is the cholesterol-CD interaction. The effect of CDs on these viral 
and cell constituents is still unclear or not entirely understood. 
In the articles, pharmaceutical and medical applications play a 
leading role, and the appearance of CDs in antiviral formulations is less 
pronounced. It is also true that many accepted antiviral molecules are 
usually soluble in water, poorly absorbed from oral formulations, or 
owing to their chemical structures like the nucleoside or nucleotide 
subunits, less suitable guests for complexation with the most common/ 
accepted CDs. Another weakness is that some of the molecules are pro- 
drugs, and the parenteral administration is the only available route. 
Although near one hundred accepted chemicals are available for anti-
viral treatments, only less than half of these compounds have experi-
mented with CDs. The currently most serious pandemic conditions set 
the focus on the weaknesses of antiviral therapy. Complexes of potential 
anti-SARS-Cov2 candidates are virtually invisible, as shown in Fig. 4, 
even when guest molecules from other therapeutic areas supplement 
this set. At the time of the manuscript preparation, the outcome of the 
intensive coronavirus research is unknown. This paper aims to demon-
strate the role of CDs in the treatment of antiviral infections. With this 
aspect in mind, the CD applications in various drug analyses are 
Fig. 1. Structural characteristic of α-, β-, and γ-cyclodextrins. Molecular Lipophilicity Potentials (MLPs) were created with JMol v14.31.2 (Jmol: an open-source Java 
viewer for chemical structures in 3D. http://www.jmol.org). 
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mentioned here superficially only. 
During the review process of this manuscript, some excellent reviews 
have appeared on pharmaceuticals [23], particularly on the nano-
encapsulation of antiviral drugs [24] and cyclodextrins [25]. The most 
common antiviral drugs and CDs discussed in detail in the publication of 
Braga et al. [25], which also includes some patented new approaches, 
and provides additional information to this review. 
2. Cyclodextrins in drug delivery 
Although the number of CD derivatives is continuously increasing, 
the number of pharmacologically accepted molecules, either as active 
components or excipients, has not changed much in the past decades. 
The presence of CDs in the GRAS list shows a similar trend. A specially 
designed curare-type antagonist Sugammadex, (octakis(6-deoxy-6-S-(2- 
carboxy)ethylsulfanyl)-γ-cyclodextrin, Bridion®), and (2-hydroxy)pro-
pyl-β- and -γCD (HPβCD and with restrictions HPγCD), and (4-sulfobu-
tyl-βCD) are approved derivatives for parenteral administration so far. 
The SB- and HP-CD derivatives are randomly (statistically) substituted 
derivatives, i. e., not only the degree of substitution (DS, number of 
substituents/CD ring) is an average value, but the numerous 
regioisomers are also present in the accepted derivatives. This kind of 
structural diversity has posed grave challenges to drug authorities and 
makes it difficult to register a new and more effective CD derivative. The 
glucopyranoside units have three, somehow different reactive hydroxyl 
groups. In CDs, the most reactive hydroxyl group is C(2)-OH. Although it 
is also true that the C(3)-OH groups are practically as reactive as the C 
(2)-OH groups, owing to the truncated cone average shape of the most 
common CDs, the C(3)-OHs sterically hindered that reduces their reac-
tivity, particularly in cases of bulkier reagents. In general, the sterically 
crowded, bulk reagents prefer the primary hydroxyls. However, it is also 
true that as the molecular complexity or symmetry increases, whether it 
is a cyclodextrin derivative with a well-defined structure or another 
good solubility enhancing property, the production costs increase 
significantly. 
While the formation of an inclusion complex may not only affect the 
distribution of drug molecules, the interaction of HPβCD, unlike the 
SBβCD, with cellular components may even be detrimental. In some 
cases, however, this effect may be beneficial. Parenteral administration 
of this drug additive can successfully cure some rare diseases [26] and 
atherosclerosis, although the mechanism is still the subject of dispute 
[27,28]. 
The methylated cyclodextrins are among the best solubilizing CD 
derivatives, but their high affinity to cholesterol causes hemolysis, at 
least in vitro. Until now, this critical drawback has prevented the 
approval of methylated CDs in pharmaceutical compositions. A meth-
ylated βCD of fewer methyl substituents (DS is 4–6), CRYSMEB, shows 
less hemolytic activity and higher biotolerability than RAMEB. 
Currently, it is near to the approval in dermal formulations only. 
The application of Sugammadex in the after-surgery recovery pro-
cesses is hopeful, but numerous medical publications have been still 
continuously finding contraindications for its applications [29]. The 
acetylcholinesterase enzyme regenerative capacity of pyridinium 
aldoximes can also be improved with the appropriate cyclodextrin de-
rivatives [30]. These regioselective cyclodextrin derivatives have 
appeared to be promising in reducing the biological effects of certain 
neurotoxins. Studies on the development and biological efficacy of this 
type of drug-targeted CD derivatives have so far been less popular, or at 
least less public. EMA published an excellent summary of currently 
approved CDs [3] on their physicochemical, physiological, and phar-
macokinetic properties. In a recent review, Chakravarty [31] outlined 
potential targets for the development of antimicrobial therapy. A better 
aspect of CD derivatives in specific applications is well-discussed in 
various recent reviews, too [32–35]. 
2.1. Non-parenteral use of cyclodextrins 
Many excellent reviews have been dealing with the CD application in 
various drug deliveries. Here this general topic is touched superficially 
only. For oral delivery, by taking care of the GRAS list recommended 
maximal CD intake, practically all the natural CDs and some derivatives 
are available. Table 1 shows the currently used CDs in various drug 
delivery systems. 
EMA just recently approved a vaginal formulation of saquinavir and 
HPβCD for prevention purposes only [36]. The main direction of vaginal 
drug developments is usually targeted at antibiotics and antifungals, and 
Fig. 2. MLP characteristic of the most common CD derivatives, (2-hydroxy)propylated βCD (DS = 5, HPβCD), randomly methylated βCD (DS = 12, RAMEB), and 
sulfobutylated βCD (DS = 7 as Na salt, SBβCD). Molecular Lipophilicity Potentials (MLPs) were created with JMol v14.31.2 (Jmol: an open-source Java viewer for 
chemical structures in 3D. http://www.jmol.org). 
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antiviral drugs are only sporadically involved in these studies, despite 
the much higher risk of some viral infections [6]. 
2.2. Parenteral use of cyclodextrins 
Since among the most common non-derivatized CDs, only the αCD is 
approved, with restrictions, for parenteral use, the number of generally 
useable CD excipients is small, actually only two: HPβCD and SBβCD. 
While, due to dominantly patent reasons, only one type of SBβCD 
(DS: 6–7, with a tight distribution of differently sulfobutylated βCDs) is 
suitable as a parenteral additive, the HPβCD has a little higher vari-
ability. The most common feature of both derivatized βCDs is that the 
substituents are predominantly pending on the secondary (C(2/3)) ox-
ygen, thus widening and lengthening the less hydrophilic cavity [37,38]. 
The hydrophobic butyl chain and the very hydrophilic sulfonate 
end-group make the sulfobutyl substitution amphiphilic. The (2-hy-
droxy)propyl group is less amphiphilic because, in the HP moiety, the 
hydroxyl group locates in the middle of this short pendant group that 
results in a characteristically less hydrophilic property. Additionally, the 
number of free hydroxyl groups in the HPβCDs is identical to the parent 
Fig. 3. Relative distribution of the publications: a) direct antiviral effects of the CDs are discussed, b) without analytical applications of CDs and patents.  
Fig. 4. Relative distribution of CD-related publications (without patents). a) distribution of CD publications within the complete set, b) the CD share in treatments of 
various infections, c) the relative distribution of the antiviral drug/CD publications. Purple bars represent non-antiviral compounds recommended for testing in 
Covid-19 treatments. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) 
Table 1 
Use of cyclodextrins as drug delivery aid, based on EMA/CHMP/ 
333892/2013 (Cyclodextrins used as excipients) guideline, as of 
October 9, 2017 [3].  
Oral βCD, γCD, HPβCD, SBβCD, RAMEB 
Parenteral αCD, HPβCD, SBβCD 
Topical  
Dermal βCD, γCD, HPβCD 
Ocular βCD, HPβCD, RAMEB 
Nasal RAMEB 
Rectal βCD, HPβCD 
Vaginala HPβCD  
a with restrictions. 
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CD. Besides the higher variability in the number of substituents, this 
higher hydrophilicity also makes the HP-CDs better libraries for drug 
molecules. 
However, it is worth mentioning that Sugammadex plays just the 
opposite role to the traditional meaning of usual drug delivery. While 
the CDs are working as a drug delivery vehicle from outside into the 
body, the Sugammadex pulls/washes out the commonly used curare- 
type aminosteroid non-depolarizing neuromuscular-blocking agents 
from the targeted cells [39,40]. 
3. Cyclodextrins in drug analysis 
About 15–20% of CD technical papers deal with the analytical 
application of CDs. The vast majority of these publications concern drug 
analysis, especially chiral separations. CDs are not only excellent chiral 
selectors but also have successful positional isomer-selector properties 
[41–43]. Due to its low reagent requirements, flexibility, and sensitivity, 
capillary electrophoresis (CE) is increasingly paving the way for 
analytical applications of CDs in pharmaceutical analyses. The CE 
method is currently not the most widely accepted pharmacopoeial 
method yet, but it is exactly the method that perfectly exploits the 
complexation properties of CDs. Pharmaceutical analysis is on the top 
priorities of medical developments, and, of course, the number of drug 
analysis publications is much more than the use of CDs in pharmaceu-
tical formulations. 
In 2020, everybody could learn the importance of various tests in the 
fight against microbial infections. Unlike conventional analytical ap-
plications, these methods use CD to remove interfering components 
from samples instead of separating similar molecules. In a fast test of a 
common bacterial infection, βCD with activated carbon can increase the 
polymerase chain reaction (PCR) test sensitivity (≈3 CFU/g) by 
removing lipids and shorten the test period in food samples [44]. Until 
now, no publication has appeared on similar studies in the antiviral PCR 
tests. Another fast post-Covid-19 testing technology, the 
micro-chromatography of immunoglobulins (Igs), uses blood droplets or 
intravenous blood samples. This test methodology, because of the not 
100% sensitivity and selectivity, many times provides a false negative 
result. The essay utilizes the different chromatographic mobilities of IgG 
and IgM, and the used microliter volume of blood sample needs a special 
in situ sample preparation. A recent publication reports the interaction 
between IgG and HPβCD, which may provide information for a possible 
development [44]. 
4. Cyclodextrins and antiviral pharmacons 
Among the near one hundred common antiviral agents [45–47], less 
than 40 have some connection to cyclodextrin, as seen in Fig. 4c, and 
only 10 have more than 5% mention together with CDs. In Fig. 5, the 
most mentioned antiviral drugs and their appearance are seen [48]. 
4.1. Small organic molecules 
Due to the aqueous solubility of the small organic antiviral mole-
cules, the CDs, particularly the polymeric CDs, are suitable for the 
controlled release of drugs [49–51]. Although numerous articles are 
published on this topic, the potentially acceptable formulations are 
difficult to find [52]. 
4.1.1. Orally administered antiviral drugs 
The most common orally administered antiviral drugs are oseltami-
vir (influenza), acyclovir and famciclovir (herpes simplex and zooster), 
entecavir, tenofovir, adefovir, lamivudine, and telbivudine (chronic 
hepatitis B). 
CDs have a minimum molecular weight (MW) of 973 Da (αCD) that is 
3–4 fold larger than small antiviral molecules, whereas the MW of most 
common CDs, the βCD (MW = 1135) and its derivatives, is even higher 
than αCD that further worsen the drug:CD weight ratio. The molecular 
weight of oral drugs is generally in the range of 225–350 Da, which 
would result in large tablets, even with a complex of 1: 1 M ratio. Besides 
the drug:CD ratio, the relatively high doses further limit the use of CDs. 
Generally, the absorption of the active ingredients is faster from CD 
complexes, i.e., the complexation can usually increase the solubility and 
improve the bioavailability, too. 
As a new combination, graphene oxide functionalized βCD/curcumin 
complex successfully inhibited in vitro the respiratory syncytial virus 
[53], but difficult to see the presence and future of such composites in 
therapy. 
4.1.2. Topical antiviral drugs 
Skin formulations dominate the topical applications, though the 
Fig. 5. Relative distribution of articles on antiviral drugs with cyclodextrins (without analytical papers).  
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number of studies on transmucosal delivery is increasing. A recent 
publication summarizes [54] the CD uses in skin formulations, so this 
topic is touched superficially only. Due to the limited transfer of CDs 
through the skin, these formulations require fewer pharmaceutical 
considerations, which widen the potential CDs in those applications. 
The eye, nasal, or pulmonary formulations represent different targets 
for drug delivery, and the CD absorption from these formulations is not 
completely clear. In those formulations, the CDs generally are for 
enhancing the aqueous solubility of drugs. Because hydrophilic antiviral 
agents are usually well-soluble in water, the CDs are, obviously, not the 
first-choice additive. A good example is the ribavirin (against hepatitis C 
and viral hemorrhagic fevers). The CD complexes of this compound are 
effective against the measles virus, but they are used in parenteral for-
mulations only, and for pulmonary delivery, a liposomal aerosol in 
combination with other antiviral agents was chosen instead [55]. 
CD-based polymers, either the CD-polymers, nanosponges, or CD- 
combinations with other polymers, can play an increasing role in 
topical applications, particularly in the mucosal and transdermal ad-
ministrations [54,56–58]. The controlled release of acyclovir in ocular 
and subcutaneous administrations from a (hydroxy)propyl methyl-
cellulose/cellulose acetate phthalate sandwiched acyclovir-βCD com-
plex was successful [49], but the composition is still far from an 
everyday application. 
4.2. Complex molecules, proteins, nucleic acids 
The gastrointestinal tract, which is targeted by oral administration, 
rarely transfers macromolecules. The majority of the CD derivatives are 
poorly penetrating through the biological membranes, too. Although 
potential CD derivatives show more variability in topical administra-
tions, attempts to formulate these drugs use only the most common CDs. 
Parenteral macromolecular formulations rarely contain CDs, as 
currently approved CD derivatives do not provide additional benefits in 
these formulations. The CDs in the local administrations have another 
advantage, besides the (potentially) controlled drug release as the 
complexation properties after the drug release can be further exploited. 
Destruction of the cell walls, eventually, the virus structures, or selective 
removal of potentially toxic components can accelerate the healing of 
wounds or skin infections [59–62]. 
Carbohydrate groups are usually unsuitable guests for CDs. Conse-
quently, oligo- and polysaccharides can only interact through hydrogen 
bridges O⋯H⋯O. This weak connection rarely has enough power for 
targeted drug delivery and can significantly limit the CD-virus in-
teractions as it leaves the carbohydrate moieties of viruses intact [16,63, 
64]. When the lipid envelope is enriched in cholesterol, successful 
microbicidal effects are found [65]. 
Because of their molecular dimensions, macrocycles are generally 
less suitable guest molecules, but the substituents attached to them can 
interact with CDs. In such cases, CD-macrocycle complexes of various 
compositions may be formed, as is the case, e.g., among the taxane 
derivatives [66]. However, a new, more effective formulation is rarely 
attractive for the profit-oriented pharmaceutical industry because a new 
composition does not always bring quick benefits and may discard 
earlier investments into the formulation developments. 
The lipid fraction of a cell is usually the perfect guest for CDs, and 
changes in membrane structure often cause cell death. Although this 
may be useful in antibacterial agents, it is less prevalent in antiviral 
therapy because, unfortunately, viruses do not have a cell wall, which 
reduces the direct virus-killing potential of CDs. Advantageously, when 
the lipid envelope has a high cholesterol content, an antiviral effect is 
reported. 
Although cyclodextrin-protein interaction can modify the secondary 
and tertiary structures [67], these effects do not always lead to dena-
turation. Due to the dynamic equilibrium, the regeneration of tertiar-
y/quaternary protein structures is generally possible, as only a few 
amino acids have an appropriate moiety for a stable inclusion [68]. 
Since the high affinity of sulfur-containing molecules to CD [69–71], 
through the complexation of the cysteine sulfhydryl group(s), the CD 
can protect the thiol moieties, thus prevents the irreversible oxidative 
denaturation of proteins. This can even increase the stability/shelf-life 
of conventional vaccines [72,73]. The most recently approved, 
one-dose vaccine [74] is formulated with ≈5% HPβCD [75], but further 
details are not available until now. 
Reports on the gene and oligonucleotide drugs are summarized in the 
book chapter of Mohammed [14]. Nucleosides and nucleotides can 
generally form loose complexes with native CDs. From a geometric point 
of view, an intact DNA cannot fit properly into the CD cavity. A DNA 
fragment can form a rotaxane-like molecular association with CDs which 
can be exploited in DNA sequencing [76,77] but less suitable for the 
entire DNA delivery. Amphiphilic CDs both as neutral and cationic 
versions have been found appropriate for antiviral oligonucleotide de-
livery [14,78–84], but their complex synthesis and structure have placed 
them only onto the shelf of promise so far. It seems possible that 
cyclodextrin-containing macromolecules are suitable for intracellular 
delivery of shorter oligonucleotides or siRNAs, though the exploitation 
of these associations is currently in an experimental phase only [80,83, 
85]. 
5. Cyclodextrins and virucidal pharmacons 
5.1. Virucidal small organic molecules 
Among the antiviral agents, some simple molecules have been on the 
playground for many years. Although some new molecules have been 
found, the research is dominantly based on the decoration of old 
structures, as seen in Scheme 1 . 
Although numerous publications are dealing with the effects of 
various CDs in antiviral drug deliveries, only a few of them can go closer 
to the accepted status. Antiviral/CD compositions in topical deliveries 
[86] can be a better playground, though this kind of application is 
restricted only for some - but important - viral infections. The various 
nanosuspensions can also be good candidates for these non-parenteral 
purposes [87,88]. 
5.1.1. Acyclovir/aciclovir 
Acyclovir (aciclovir), is one of the oldest nucleoside analog antiviral 
drugs. Oral, mucosal, and transdermal absorption are weak, and only 
10–20% absorb from oral formulations. Although it can be administered 
internally, the dominant application is a topical formulation despite the 
low absorption rate. Aqueous solubility is moderate, and though con-
version to the sodium salt may increase it, the bioavailability of the 
ionized form remains low [89]. 
The cyclodextrin complexation can considerably increase the solu-
bility (1.3–2.7-fold) and oral bioavailability (≈1.6-fold) [86,90,91], but 
more expressed in transmucosal processes where the HPβCD complexes 
are the most effective [86,92–94]. The HP group not only extends the CD 
cavity but can form hydrogen bonds with a nucleoside. The limited 
absorption of the CDs potentially allows the use of unsubstituted CDs, 
too, and the higher nonaqueous solubility and random structure of 
HPβCD provide the adequate complexing ability for many active in-
gredients [86]. 
Amphiphilic CDs containing ester moieties can increase both the 
bioavailability and antiviral effect as concluded from the membrane 
penetration studies [51]. Polymeric CD composites work as smart 
components in drug delivery, though owing to their generally undefined 
structures, they are more suitable for topical application [52,95,96]. 
Although transdermal drug delivery is also the primary target of various 
polymeric CDs [97,98], no information is available in real applications. 
Dominantly the orally approved CDs and derivatives are still recom-
mended for skin formulations [3]. 
Although some antiviral molecules, including aciclovir, can be con-
jugated to ferrocenyl-CD complexes [99], their pharmacological use is 
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expected only in the distant future. 
5.1.2. Cidofovir, ganciclovir, imiquimod, ribavirin, tenofovir 
These molecules have been developed against various viruses, basi-
cally cytomegalovirus, HIV and hepatitis viruses, and cancer. They have 
numerous side effects and drug interactions. Reliable data about their 
aqueous solubilities are hard to find in online databanks, which often 
contain very diverse, many times estimated data only. Characteristic 
examples are ribavirin [100], which has 14.2%, >10%, 0.33%, and 
imiquimod [101] with ≈2.5%, ≈0.6% on the homepage of a known 
chemical database. In technical papers, 7.9% for ribavirin [102] and 
0.24% for imiquimod [56] are reported. 
Today, cidofovir treatment uses intravenous administration only. A 
cell-targeted polyethyleneimine-modified βCD-nanotube combination 
vector is reported to increase cellular internalization and reduce the 
dose and side effects [103]. 
Ganciclovir has been approved for medical use more than 30 years 
ago and administered both oral and intravenous ways. The oral ab-
sorption is low, and some topical applications are also known. The 
aqueous solubility is in the range of ≈0.4–0.9% range. CD complexation 
can increase not only its solubility but the bioavailability, as well. 
Interaction with natural CDs has been tested, and β- and γCD showed 
some significant improvements in the physiological properties by 
decreasing the LD50 value. The βCD can form a complex with ganci-
clovir only [104]. Since the symmetrically methylated βCD, DIMEB 
(heptakis(2,6-di-O-methyl)- βCD) can enhance transepithelial 
Scheme 1. Most cited antiviral compounds together with cyclodextrins.  
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permeability, increase bioavailability, but this βCD derivative is actually 
out of play due to the limited availability of isomeric pure DIMEB and 
price. The fine-chemical version of DIMEB is much more a high DS (≈14) 
RAMEB due to its low isomeric purity (≈35–50%) and with which 
commercial RAMEB (DS ≈ 12) has almost the same advantageous 
properties. 
Imiquimod has been introduced into anti-cancer and immunomod-
ulatory therapy for more than 20 years. Aqueous solubility is very low 
(≈0.02%) and is used primarily in topical medications as a cream. 
Mannosylated βCD, HPβCD, carboxymethylated βCD, and βCD-based 
nanosponges can improve both aqueous solubility and bioavailability 
[56,105]. 
Ribavirin is a guanosine analog wide-spectrum antiviral molecule 
with noticeable aqueous solubility. Although it has some teratogenic 
effects, it has been used as a medicine for almost 40 years in oral and 
inhalation formulations. Complexation with native α-, β- and γCDs 
increased the antiviral activity [106–110]. It is suspected that αCD and 
HPβCD increase the transfer through the brain-blood barrier and 
improve the antiviral efficacy in virus encephalitis by suppressing the 
virus replication [110,111]. 
Tenofovir is an oral antiretroviral drug from the beginning of the XXI 
century, and many times it is combined with other antiviral compounds. 
It has a high aqueous solubility (≈1.5%), particularly its phosphate ester 
or salt forms. The combination with HPβCD considerably increases its 
antiviral effect and accumulation in various tissues [112], despite that in 
a hydrogel formulation HPβCD, HPγCD, and SBβCD showed no solubility 
enhancement [113]. 
5.1.3. Azidothymidine (AZT, zidovudine), lamivudine, gemcitabine 
AZT is among the first approved anti-HIV drugs, both as treatment 
and prevention. More recently, its combination with lamivudine or 
acabavir-lamividune can leave the HIV exclusivity. While the combi-
nation of zidovudine with other virucidals is relatively new, lamivudine 
occurs in several formulations, but the stand-alone application is less 
common. These antiviral compounds are highly soluble in water, and 
although typically oral formulations use lamivudine, AZT is also 
administered in infusions. 
A study on the glycosidic bond scission in nucleosides suggests a 
beneficial effect of CDs (native CDs, HP-, and methylated βCDs) on the 
chemical stabilities [114]. An increase of the low aqueous solubility of 
AZT by various CDs reported (from <0.01 mg/ml up to ≈0.05 mg/ml), 
although much higher solubilities of pure AZT can be found in various 
databases (10–50 mg/ml) [115]. In parenteral formulations, the HPβCD 
enhanced permeation across the blood-brain barrier and successfully 
substituted the co-solubilizer DMSO in various formulations, particu-
larly in the high-dose treatments [116]. The less stable polymeric 
version of the CD-based polymers, the nanosponges, showed noticeable 
complexation abilities toward AZT and demonstrated extended chemi-
cal stability. Anionic CDs (sulfated CDs) showed synergistic effects with 
AZT [117]. The SBβCD combination with zidovudine-lamivudine 
showed a sustained release behavior, reducing the daily drug adminis-
tration frequency [118]. 
Recently, many researchers study metal-organic networks (MOFs) 
[119] in drug delivery systems that can be suitable in antiviral drug 
formulations. The complexation can extend their applicability in various 
pharmaceutical compositions, whether in monomeric or polymeric 
forms of CDs this field is, for the time being, still of more scientific in-
terest. A new excipient can further prolong the life-cycle of AZT-like 
virucidals. 
Gemcitabine is a fluoro-cytidine analog with primarily antitumor 
activity and is administered intravenously [120]. Although its hydro-
chloride salt is well soluble in water (≈4%), its chemical stability in 
aqueous solutions is far from optimal [121]. Various CD derivatives, 
namely SBβCD [122], and positively charged CD derivatives (guanidino 
and aminoalkyl CDs) [123,124] can successfully increase its activity, but 
among these derivatives, only the SBβCD has perspectives as an accepted 
parenteral drug additive. The antitumor effect can be even more effec-
tive in combination with the HPγCD/curcumin complex. In the last years 
discovered its broad-spectrum virucidal properties against human en-
teroviruses [125,126]. While the antitumor therapy usually needs 
parenteral administration, an intranasal formulation has shown a broad 
spectrum of antiviral activity [125–128]. 
The aqueous solubility of gemcitabine is good (≈4%), and CD 
complexation can influence its releasing and absorption properties. 
Several positively charged CD derivatives have been synthesized [123], 
but actually, HPγCD [129] is the only suitable candidate for 
gemcitabine. 
5.1.4. Efavirenz 
Efavirenz is an oral antiretroviral drug that is often administered in 
combination with other antiviral molecules, like emtricitabine and 
tenofovir. Although it has numerous side effects and restrictions as not 
recommended in pregnancy, it is on the WHO list of essential medicines 
and is accepted worldwide as an antiviral pharmacon [130]. 
Efavirenz has low aqueous solubility (<1 mg/100 ml) and is usually 
administered orally once a day. Despite the high dose, the plasma con-
centration slowly reaches a maximum only, making it a suitable candi-
date to improve both properties in a host-guest complex [131]. Due to its 
structural properties, this molecule appears to be less appropriate for 
strong interaction with most CDs. The use of βCD nanosuspension [132], 
γCD [133], HPβCD [133,134] and -γCD [133], or RAMEB [135] could 
improve its physicochemical (≈10-80-fold solubility enhancements) and 
pharmacokinetic properties (≈3-fold dissolution rate). Those composi-
tions required a third component to achieve the desired effects. Among 
the tested CDs, HPβCD with arginine significantly increased the aqueous 
solubility (≈60-80-fold) and bioavailability [134]. Although the 
three-component system was found better than the binary complexes, 
the calculated apparent stability constant of the complex, nearly 1000 
M− 1, appears to be exaggerating, which is a general deficiency of 
apparent complex stability constants calculated from solubility 
isotherms. 
5.1.5. Oseltamivir 
Oseltamivir was developed to treat common influenza viruses (A and 
B) in patients with high-risk complications that showed moderate 
resistance to H1N1 (swine flu), H3N2, and H5N1 (bird flu) viruses. It is 
moderately soluble in water (≈0.2%) and has a good bioavailability 
(>80%), is therefore usually administered orally. Oseltamivir metabo-
lizes fast, and the urine eliminates it and its metabolites almost 
quantitatively. 
Complexation with βCD primarily targets to mask the bitter taste of 
its phosphate [136]. The formulation has not been approved by any 
authority so far. 
5.1.6. Darunavir, lopinavir, ritonavir, saquinavir, dapivirine 
High molecular weights of this group of antiviral molecules can 
result in a high drug/CD weight in formulations. Darunavir is one of the 
latest antiretroviral oral drugs. It is commonly used with ritonavir 
because, despite its moderate aqueous solubility (≈0.7%), the relatively 
high absorption rate increases bioavailability and can reduce its amount 
to a single dose. The two aromatic groups, especially the p-amino-
benzenesulfonic group, are suitable for complexation with natural hosts. 
A combination of a βCD complex and hydroxyethylcellulose was 
developed almost immediately after its appearance for topical treat-
ments [113]. The HPβCD complex increases darunavir aqueous solubi-
lity (≈14-fold), while the effect of HPγCD and SBβCD was similar, but 
somehow smaller (HPγCD ≈6-8-fold SBβCD ≈11-12-fold), though no 
solubility enhancements for tenofovir were observed. The HPβCD 
complex also increased the bioavailability of darunavir [113,137]. 
AIDS medications have been using lopinavir for more than 20 years. 
Although 1,2-propylene glycol dramatically increases its aqueous solu-
bility (<0.001% =>≈0.1%), applied alone poorly absorbs from the oral 
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formulations, while the combination with ritonavir can improve both 
the solubility and bioavailability. 
Despite the many suitable aromatic moieties, only HPβCD and 
RAMEB resulted in moderate solubility enhancement (≈10-fold) of 
lopinavir [138]. An in-silico designed HPγCD of high DS could further 
improve its physicochemical and physiological properties [139]. 
Ritonavir has been used in antiretroviral therapy since 1996, 
administered orally, more recently in combination with other antiviral 
drugs as mentioned above. Although its aqueous solubility on its own is 
low (<0.04%), the combination of other antiviral components generally 
increases the solubility of all molecules. Despite that this compound 
contains numerous suitable substituents for the complexation, only βCD 
[140] and HPβCD [141] could moderately improve the aqueous 
solubility. 
Saquinavir, as its mesylate, has moderate aqueous solubility (≈0.2%) 
but low oral bioavailability. The combination in oral formulation with 
other antiviral molecules in AIDS medication, as lopinavir and/or rito-
navir, is more common than the administration on its own. HPβCD, 
together with hydroxyethyl cellulose in hydrogels [113] or polyethylene 
glycol matrix [142], can increase its bioavailability in vaginal formu-
lations. Increased aqueous solubility of saquinavir in RAMEB (=>≈1%) 
[143] and HPβCD(=> ≈1–1.5%) [144] complexes that improved the 
absorption properties through the gastrointestinal tract, as well. 
Dapivirine is an almost insoluble in water (<0.002%) anti-HIV drug 
molecule which is dominantly intended to use for transmucosal formu-
lation application, and oral or parenteral administration against hepa-
titis E and influenza viruses is pending [144]. As a vaginal preventive 
formulation has been approved in the mid of 2020 [36]. Complexation 
increases the aqueous solubility, until now HPβCD (≈3-4-fold), HPγCD 
(≈2-3-fold), and SBβCD (≈20-fold [145] or ≈60-fold [113]) have been 
used in a combination with hydroxyethyl and hydroxypropylmethyl 
celluloses, although in the accepted formulation none of the applicable 
CDs are used. 
5.1.7. Amantadine 
Amantadine has been used selectively as an oral prophylactic agent 
against the influenza A virus since the early 1960s. However, since the 
early 1980s, when the first publication appeared about drug resistance, 
the incidence of resistance has been steadily increasing. Although its 
importance as an antiviral agent is gradually diminishing, it is early to 
bury it because it inhibits the virus’s genetic material release. In com-
bination with other virucidals, it can control the spreading of similar 
viruses. 
As a salt, it is highly soluble in water and forms a stable complex with 
βCD, which has apparent complex stability constant in the range of 104 
M− 1 [146]. Later various CD derivatives, namely SBβCD [147], car-
boxymethylated βCD [93], and heptacarboxyl-βCD [148] were also 
tested., but the last one is not a cyclic glucuronic acid variant of βCD, but 
a 1H-1,2,3-triazole-4-carboxylic acid substituted βCD. The excellent 
guest properties of adamantyl derivatives have led to the study of 
various biopolymers in controlled release experiments. A common 
feature of these attempts is the loose connection to the antiviral prop-
erties of amantadine. 
5.1.8. Antiviral drugs with minimal cyclodextrin literature impact 
Dolutegravir sodium (DTG) loaded nanoparticles HPβCD-based 
nanosponges successfully enhanced the CNS uptake by intranasal 
administration [149]. 
The aqueous solubility of rilpivirine could be increased around 4-fold 
using βCD and HPβCD [150], while βCD nanosponges somehow 
increased the oral bioavailability, too [151,152]. 
5.2. Small antiviral organic molecules with potential anti-SARS-Cov2 
property 
Compounds (Scheme 2) in this section have just recently been placed 
in the repurposing category because anti-coronavirus effects have been 
found and assumed to be effective against SARS-Cov2, as well [45]. 
5.2.1. Disulfiram 
Disulfiram inhibits the acetaldehyde dehydrogenase enzyme, and 
this property allows its use in the treatment of chronic alcoholism. 
Recently some antiviral effects against SARS and MERS viruses have 
been reported [153]. Its aqueous solubility is low (<0.02%) 
The rich sulfur content is suitable for CD complexation, and the use 
of HPβCD increased in topical administration not only its aqueous sol-
ubility (up to near 1%) but bioavailability (≈3-fold), too [71]. 
5.2.2. 6-Thioguanine 
Thioguanine is developed as an antimetabolite administered in oral 
formulations against various leukemias and has many side effects [154]. 
Its aqueous solubility near-neutral pH is low (<0.1%), but alkaline so-
lutions can ionize it, and the solubility increases dramatically. 
The antiviral properties of 6-thioguanine against rotaviruses have 
recently been discovered [155]. Its protease inhibitory properties may 
allow inhibition of SARS-Cov2 replication [156]. 
A non-analytical application of the 6-thioguanine/CD complex uses 
gold nanoparticles for drug delivery [70]. 
5.2.3. Mycophenolic acid 
Mycophenolic acid was discovered more than a hundred years ago 
[157], and its long journey from antibiotic to a virucidal molecule is an 
instructive story as summarized in an excellent review. Its principal 
physiologic effect is immunosuppression. Its protonated form is poorly 
soluble in water (<0.04%) around the neutral pH, but 1 M NaOH in-
creases it dramatically. 
Succinyl(2-amidoethyl)1 βCD-based [158,159] liposomal polymeric 
gels can form a complex of native mycophenolic acid. 
N-Morpholinoethyl ester of mycophenolic acid was successfully 
complexed by βCD [160] in topical [161] and controlled release for-
mulations [162]. 
6. Cyclodextrins and potential anti-SARS-Cov2 molecules 
Although there are huge expectations worldwide for the develop-
ment and rapid production of a safe, general Covid-19 vaccine for 
everybody, researchers are still looking for a well-known traditional 
drug to reduce the symptoms of SARS-Cov2. Dozens of clinical trials 
have been launched to test a variety of known molecules that can 
directly or indirectly inhibit the spread of the virus or, in more severe 
cases, increase survival. More than a year after the outbreak, we still do 
not know enough about the virus, its behavior, and how to effectively 
treat the disease. The scientists started to find the most effective com-
pounds, obviously, among the already known drugs based on the 
mechanism of action and infection analogies. Many medicines and 
therapies have already been named miracle cures, which were then, 
even the following week, pushed into the background due to ineffec-
tiveness or even adverse effects. It is equally valid for HCQ, an otherwise 
effectively used drug in the cure of malaria and autoimmune diseases, 
the antiviral favipiravir, or fenofibrate (Scheme 3), which reduces blood 
cholesterol [163]. Last spring, one major cyclodextrin manufacturer 
announced its recommendation of βCD derivatives [164] as host mole-
cules for some supposedly effective anti-Covid-19 pharmacon [165], as 
solubilizers of remdesivir (SBβCD) [166] and lopinavir-ritonavir com-
bination (HPβCD), and as a taste masker for oseltamivir (βCD) [136]. 
The first enthusiasm against Covid-19 already envisioned the protecting 
1 The authors’ best knowledge suggests that despite the incorrect starting βCD 
structure shown – because the commercially available succinyl βCD has 
different structure – in the publication of Park et al. ([159]), the synthesized 
compound structure might be correct. 
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properties of βCD-chlorhexidine containing mouthwashes [167]. As in 
many other cases, a few months later, it was the authors who refuted the 
anti-SARS-Cov2 effect of many types of mouthwashes [168]. 
6.1. Cetylpryridinium chloride 
Cetylpyridinium chloride is an amphiphilic compound that has been 
widely used for decades in personal care products such as mouthwashes, 
throat sprays, breathable sprays, and the like. This compound has 
antiseptic properties, effectively kills bacteria and fungi [169], disrupts 
the lipid layer of membranes [170], reduces the expression of viral genes 
[171], and is popular in antimicrobial products due to its relatively low 
toxicity. Recently, a beneficial effect has been observed in the preven-
tion of SARS-Cov2 infection [172–174] that has generated more detailed 
studies on the antimicrobial mechanism. 
Although the aqueous solubility is high (≈5%), both the aromatic 
moiety and the hydrophobic long alkyl-chain can form complexes with 
CDs. The CD complexes are suitable for controlled release [175]. 
6.2. Favipiravir 
Generic favipiravir is an RNA polymerase inhibitor used mainly in 
Asian countries to treat more severe flu cases. One publication discussed 
in detail the mechanism of its effect, finding lethal mutagenesis of SARS- 
Cov2, though the published results did not yet provide convincing evi-
dence for efficacy, primarily due to inadequately followed study pro-
tocols. However, favipiravir was more effective against Covid-19 than 
the combination of lopinavir and ritonavir [176,177]. 
Favipiravir is poorly soluble in PBS (≈0.01%), and its effective dose 
is relatively high (600–1600 mg/day). A serious drawback, in the best 
case, the 1:1 complexation of βCD would require a minimum of 
≈4.3–13.5 g/day βCD orally. Although large tablets could resolve these 
amounts only, the βCD intake would be well above the EMA recom-
mendation of ≈0.5–1 g/day. The more tolerated other CDs oral intake 
can be higher, 1–10 g per day, but their molecular weights are even 
higher than the βCD. So far, no favipiravir/CD complexes are reported in 
the literature, although the molecular structure suggests only low sta-
bility constant or little improvement in aqueous solubility. 
6.3. Remdesivir 
Remdesivir targets the inhibition of an enzyme that is necessary for 
the genetic material copy of a virus, and it was among the first targets of 
drug reconsiderations against the symptoms of Covid-19. Remdesivir is 
still the subject of studies to assess its effectiveness [178–182]. Although 
it is allowed to use in Japan, and both FDA and EMA have also permitted 
its therapeutic use within the USA and EU in less severe infections, some 
conditions of use and biological effects are still unclear. 
Low aqueous solubility at neutral or slightly acidic pHs is its serious 
drawback of parenterally administered remdesivir. To increase the sol-
ubility, SBβCD is used, which, while having much worse complexing 
properties than HPβCD, makes its anionic property suitable for the sol-
ubility enhancement of an ionizable molecule at a tolerable pH. SBβCD 
has fewer side effects than HPβCD, though the drug/CD weight ratio is 
worse. The current formulation contains, in the dissolvable powder 
contains near 3% remdesivir, and about half of this in the liquid infusion 
formulation [183]. Increasing the drug/CD ratio is more than a wish. In 
some formulations, using organic co-solvents and/or ultrasound-assisted 
Scheme 2. Small antiviral molecules are supposed to have anti-SARS-Cov2 properties.  
Scheme 3. Recommended virucidal drugs for testing against Covid-19.  
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dissolution can result in better solubilization of remdesivir by SBβCD 
[184]. The sulfobutyl group is a relatively strong acid, almost entirely 
neutralized by sodium ions in the commercial product. The solubility 
enhancement of this CD derivative is more related to some non-ionized 
sulfobutyl groups than to the formation of inclusion complexes. These 
protonated sulfonic acid groups provide a strongly acidic microenvi-
ronment for remdesivir. The substituents mainly locate on the secondary 
hydroxyl edge of βCD, which not only widens the cavity but may pro-
mote the ionization of remdesivir due to the high density of negatively 
charged groups. A recent publication that appeared during the revision 
process made attempts to demonstrate some lipophilic interaction be-
tween remdesivir both the cyclodextrin and the sulfobutyl side chain, 
furthermore, NMR and molecular modeling make the interaction of 
ionizable groups also possible [185]. The NMR studies suggest a more 
realistic ensemble of the guest than as figured on a drug development 
forum in the mid of 2020 [186]. 
Although the salt formation can be more expressed than inclusion 
formation, finally, it is entirely irrelevant for the current formulation. A 
significantly increased drug content and enhanced efficacy in patients in 
the early stages of Covid-19 may accelerate recovery from the disease, 
decrease the side effects of high SBβCD dose, reduce the hospital burden 
and patient suffering. 
6.4. Dexamethasone 
Dexamethasone is a corticosteroid immunomodulator introduced to 
medical treatments in the early 1960s. Many ways, including oral for-
mulations, are available to treat the patients. This drug is on the NIH 
recommendation list [187] after it was found effective in reducing 
mortality rates in critical stages in Covid-19. Although its wide appli-
cation in antiviral therapy is still under study, the available data suggest 
its beneficial effect on infected patients [188,189]. Currently, a single 
daily dose of medication appears to be sufficient, as it successfully in-
creases patient survival in either injectable or tablet form, and this 
long-lived molecule is one of the inexpensive treatments. 
Although the aqueous solubility is low (<0.01%), its bioavailability 
is over 80%. From the beginning of its life-cycle, numerous reviews deal 
with its interactions with various CDs and CD derivatives [190–192]. 
The CDs can increase the aqueous solubility of dexamethasone and 
the residence time in the body. Many times topical applications can 
provide faster absorption and better bioavailability, too [193–197]. 
6.5. (Hydroxy)chloroquine 
Hydroxychloroquine and chloroquine are oral anti-malarial drugs 
worldwide that have also been used since the middle of the last century 
and to treat rheumatoid arthritis and porphyria, as well. Its use in Covid- 
19 treatments [198,199] resulted in the most controversial compound 
due to the extensive political tailwind [200]. In some cases, it has had a 
beneficial effect on patients infected with SARS-Cov2 [201], but in 
addition to serious side effects, more questions have raised than 
answered [202,203]. 
Although chloroquine (CQ) and hydroxychloroquine (HCQ) are hy-
drophilic drugs (CQ: <0.01%, diphosphate> 5%, HCQ <0.03%,> 22%), 
their solubility and bioavailability can be further improved by βCD 
complexation [204]. Besides, the reduction in some side effects has also 
been reported. HCQ also forms a complex with both α- and βCD [205, 
206], which can be exploited in pharmaceutical compositions within its 
accepted scope. 
CQ and HCQ also have adverse systemic effects that can be life- 
threatening, especially at high doses. Unfortunately, an attempt to 
combine antiviral azithromycin with HCQ neither had any positive ef-
fects [207]. 
Although βCD may improve the solubility of both CQs, this is still of 
little importance for the treatment of Covid-19 in comparison with the 
reported side -effects [208]. 
6.6. Ivermectin 
Although ivermectin is principally intended for use in animals, there 
are also some human formulations [209,210]. Although the replication 
of SARS-Cov2 was successfully inhibited in vitro [211], after a short 
period of study, NIH does not recommend it against SARS-Cov2. The 
high dose and many side effects have put it into a non-recommended 
status [212]. 
This macrocyclic compound, despite the conjugated 2,6-dideoxy-4- 
O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O- 
methyl-alpha-L-arabino-hexopyranoside moiety, practically insoluble in 
water (<0.04%). Contrary to low aqueous solubility and bioavailability, 
it is used in oral formulations [213]. 
The ivermectin/βCD complex has a large apparent stability constant 
(1700 M− 1), though the aqueous solubility of the complex is still low: in 
the preparation of the complex nanoprecipitation forms. Although an 
agricultural formulation mentions the ivermectin/RAMEB complex 
[214], detailed information is not available. 
After the submission of the first version of this manuscript, the FDA 
and EMA withdrew ivermectin from the ‘recommended for testing’ list 
[215,216]. 
6.7. Fenofibrate 
Fenofibrate is used to lower blood lipids, but since this type of statins 
has shown a less significant reduction in the risk of heart disease or 
death, its popularity has dropped. Its prolonged use causes some hepa-
totoxic effects, too. The mechanism of action of SARS-Cov2 suggests that 
Covid-19 leads to lipid deposits in the lung. This effect increases the 
severity of the infection. Although this drug is safe, further compre-
hensive studies are needed to prove its effectiveness against the new 
coronavirus, as there is currently no direct evidence that Covid-19 is 
beneficial for patients [232]. 
The aqueous solubility (<0.01%) and oral bioavailability of fenofi-
brate are very low, but some nanoparticle formulations can improve 
these properties [254]. 
As an old drug, numerous attempts have tried to increase the 
aqueous solubility by complexation. HPβCD could increase the fenofi-
brate concentration in water (up to ~1%) and improve its absorption 
[255]. The solubilizing power of βCD could not outperform the results of 
HPβCD [256]. Attempts with βCD in the presence of hydroxypropyl 
methylcellulose improved the redissolution properties of fenofibrate 
[254,257]. 
6.8. Lopinavir and ritonavir 
Antiretroviral drugs, as lopinavir and ritonavir, are commonly used 
together to treat HIV-infected people, and the recently found some anti- 
SARS-Cov2 effects [177] has put lopinavir/ritonavir combination to the 
NIH recommended-to-try list. Later, NIH withdrew this recommenda-
tion because the clinical trials have not demonstrated the benefits of 
protease inhibitors in Covid-19 [217]. The discussion of these virucidals 
is in a previous section. 
6.9. SNG001 (Interferon-β) 
Interferon-β is used to treat chronic obstructive pulmonary disease, 
and this product can reduce the amount of MERS-COV virus. Although 
inhalation of interferon-β, SNG001 has also shown positive results in 
ongoing Phase II SARS-Cov2 studies, detailed information is not yet 
available, and independent researchers have not confirmed it so far 
[218]. 
Methylated cyclodextrins can positively influence the interferon-β 
secretion by the RAMEB-cholesterol interaction in cell membranes 
[219], but this connection to SARS-Cov2 viral infection is still unclear. 
During the preparation of the manuscript, a new molecule was 
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approved for preclinical studies for Covid-19 treatment after ptilidepsin 
showed greater efficacy than remdesivir [220]. Two other new drug 
candidates (bepridil and thapsigargin) also showed beneficial properties 
against SARS-Cov2, although the results have not been confirmed yet. 
These structures are shown in Scheme 4. The previously mentioned 
compounds are more or less synthetic organic substances, while gly-
cyrrhizin is a natural molecule widely used in various food products. 
This compound has been studied with varying degrees of success against 
different viruses [221–223]. 
6.10. Glycyrrhizin 
A principal component of licorice (liquorice, liquirizia) is glycyr-
rhizin. Last year periodically appeared several communications on 
glycyrrhizin-containing products in the prophylaxis of SARS-Cov2 
spreading [224] or even patient treatment [223,225]. Up to now, the 
scientific community has not yet clearly confirmed the preventive 
properties of these products. FDA has put some warning messages [226, 
227] about fake natural products, scientific papers report its efficacy 
against Covid-19. Glycyrrhizin is a saponin, a glycosylated plant steroid 
analog. After hydrolysis by gastrointestinal bacteria, aglycone is 
completely absorbed and then metabolized in the bloodstream. CD 
complexation can improve the chemical stability of the aglycone, The 
chemical stability of aglycone can be improved by CD complexation, 
which in some cases can reduce the adverse effects of other drugs [229, 
230]. Glycyrrhetinic acid conjugation to CD showed visible antiviral 
activity against influenza A (H1N1) in some cases [231]. 
6.11. Plitidepsin (Dehydrodidemnin B, Aplidin) 
Plitidepsin is a cyclic oligopeptide, possesses antitumor, antiviral, 
and immunosuppressive activities, isolated from a marine species 
(Aplidium albicans, an ascidian). In Australia, it has limited clinical 
approval in a dexamethasone combination against relapsed and re-
fractory multiple myeloma. In the drug repurposing screening, the 
preclinical efficacy against SARS-CoV-2 is found by inhibiting the 
translation mechanism in the virus [232]. Plitidepsin has been shown to 
induce apoptosis and was accepted as an orphan drug in 2003. Some 
results suggest its mechanism of action is related to the cholesterol 
content of the SARS-Cov2 lipid shell [233]. Although it contains a 
suitable methoxybenzyl group for CD complexation, no CD complexes 
have been described so far. 
6.12. Bepridil and thapsigargin 
Bepridil is an old calcium channel blocker to treat angina and atrial 
fibrillation but is supposed to cause ventricular arrhythmia. A combi-
nation with amiodarone successfully inhibited the Anthrax lethal toxin 
entry into host cells [234], founded its presence in an antiviral drug 
repurposing study, and showed a 100% survival rate of ebola infected 
mice was published [235]. The two phenyl moieties can form CD com-
plexes, although this property is exploited in analytical applications 
only. 
Thapsigargin is a sesquiterpene lactone inhibition effect against 
coronavirus, respiratory syncytial virus, and influenza A virus [236]. 
This inhibition could be extremely useful in the prophylaxis of viral 
infection. The principal mechanism of inhibition is blocking the Ca2+
ATPase pump. Although its structure is weakly suitable for the complex 
formation with CDs, together with RAMEB, it may increase the efficacy 
as reported in an in vitro study [237]. 
A recent publication set the focus of the IgG-HPβCD interaction 
which can be utilized in the Ig-based therapy of various cancers and 
autoimmune diseases [44] and although the utilization potential of this 
interaction in oral or intranasal vaccinations has not been studied [238]. 
7. Pharmaceutically active cyclodextrins 
Nowadays, more and more facts show that CDs are not as inert 
molecules as believed for many decades [239]. Of course, the pharma-
cological activities are about their complex formation abilities. 
Completely reverse action is when a specifically derivatized CD is the 
guest molecule for pore-forming proteins. Although some symmetrically 
substituted aminocyclodextrins have adjuvant effects, particularly in 
anthrax treatments [240] or C. perfringens infection [241], their phys-
iological properties are still not entirely studied. 
Although there are attempts to use CD derivatives as antiviral agents, 
a real therapeutic utilization is far below the horizon. It is much more 
due to their complicated and expensive synthesis [242], industrial 
production difficulties, and eventually their inadequate in vivo proper-
ties. Among the authorized CD derivatives, the anti-HIV properties of 
HPβCD had been a promising candidate in contagion prevention but the 
initial enthusiasm soon was followed by a long silence [65,243]. 
Some CD derivatives have antiviral properties on their own, but 
confirmation of these findings is still in the research phase [244]. In a 
recent report, per-6-thioalkylsulfonic acid βCDs against HIV, HIV, ebola, 
and zika viruses were effective. These amphiphilic CD derivatives have 
excellent antiviral activity at the tens of μg/ml level [6]. 
Anti-HIV agents showed synergistic interaction with many sulfated 
oligo- and polysaccharides or sulfated CDs. However, cross-resistance of 
sulfated βCD with JM3100-resistant virus also suggests that CDs may not 
only have beneficial effects in antiviral therapies [245]. 
8. Toxicologic considerations 
The literature on CD toxicology is continuously increasing. Many 
reviews summarize this aspect of CD applications, and here only some 
most important points are mentioned [190,246–249]. 
The CDs practically do not absorb through the gastrointestinal tract, 
which allows a better variety of applicable CDs in oral and topical for-
mulations to enhance aqueous solubilities and bioavailabilities. The 
topical formulations are in an even better situation because insoluble 
CD-based polymers can further widen the potentially applicable CDs. 
In general, in parenteral formulations, the statistically substituted 
CDs are most suitable, as the random arrangement of substituents rarely 
Scheme 4. Some new candidates in Covid-19 treatment.  
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leads to poorly soluble complexes. Random substitution has another 
advantage as it has non-uniform substitution: due to the mixture of CDs 
substituted in different ways, this type of derivatives can serve as a li-
brary for a wide variety of guest molecules. Some organ damage phe-
nomena are associated with the low solubility of crystalline CD 
complexes. The high affinity to cholesterol is at least as crucial as that 
seen for many neutral βCD derivatives. The complexation of cholesterol, 
this principal component of cell membranes, can destroy the cell 
membrane and lead to cell death. This principally characterizes meth-
ylated CDs, but many neutral, less hydrophilic CD derivatives have af-
finities to cholesterol, too. In the case of HPβCD, it is DS-dependent, and 
attaching an ionizable substituent to RAMEB, this property can be 
reduced, as in the case of succinylated RAMEB. The beneficial effect of 
endosomal cholesterol removal in Nieman-Pick disease type C treatment 
[250] also brings a new complication as the HPβCD accumulates 
cholesterol in the lungs [251]. 
9. Conclusion 
This review has attempted to summarize the current knowledge on 
the interaction between different virucides and CDs. The Covid-19 
pandemic has caused a boom in publications on viruses and resulted 
in a constant and rapid change in the information available, with often 
contradictory results week after week, even in peer-reviewed journals. 
Bioavailability improvements of drugs are the principal purpose of 
CD complexations, and these property improvements often reduce side 
effects, too. Less than half of the just over 100 approved antiviral mol-
ecules have been tested with cyclodextrins. Not all virucides are 
appropriate to interact with native CDs, but the substitution of the CD 
hydroxyls can expand the CD cavity, converting them into suitable hosts. 
The statistically derived CDs, HP- and SBβCD, are the most commonly 
used host molecules, as they are also parenteral drug carriers. While oral 
and topical formulations can use both native and methylated CDs, CD 
polymers and nanosponges are mainly suitable for topical applications. 
Due to the Covid-19 pandemic, many old drugs have been repur-
posed, and most of them have no CD history. The new antiviral mole-
cules usually have a high MW, which provides a favorable host-to-guest 
mass ratio, while their complex structures often contain a suitable 
moiety to interact with CDs. 
The interaction of CDs with peptides, proteins, and nucleotides 
makes CDs suitable adjuvants for vaccines or drug vectors, opening new 
research directions in antiviral therapy. 
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(Eds.), Elsevier (Pergamon, New York vol. 3, 1996, pp. 57–188, https://doi.org/ 
10.13140/RG.2.2.35859.68642. 
[39] C. Meistelman, T. Fuchs-Buder, J. Raft, Sugammadex development and use in 
clinical practice, Curr. Anesth. Rep 3 (2013) 122–129, https://doi.org/10.1007/ 
s40140-013-0015-8. 
[40] M.-Q. Zhang, Drug-specific cyclodextrins: the future of rapid neuromuscular 
block reversal, Drug, Future Times 28 (2003) 347, https://doi.org/10.1358/ 
dof.2003.028.04.742715. 
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